Skip to main content
Lincoln Pharmaceuticals ltd. logo

Lincoln Pharmaceuticals ltd. — Investor Relations & Filings

Ticker · LINCOLN ISIN · INE405C01035 LEI · 3358004B6OBJNW8RTT10 BSE.NS Manufacturing
Open in API
Filings indexed 453 across all filing types
Latest filing 2022-06-18 Major Shareholding Noti…
Country IN India
Listing BSE.NS LINCOLN

About Lincoln Pharmaceuticals ltd.

https://www.lincolnpharma.com/

Lincoln Pharmaceuticals Ltd. focuses on the development, manufacturing, and marketing of a diverse range of therapeutic formulations. The organization operates advanced manufacturing facilities certified by international standards, including WHO-GMP. Its portfolio spans multiple areas such as anti-infectives, cardiovascular, gastrointestinal, respiratory, and pain management. The company is recognized for its research and development initiatives, particularly in Novel Drug Delivery Systems (NDDS). Key offerings include specialized treatments for tinnitus and a wide array of formulations in dosage forms like tablets, capsules, liquid orals, and injectables. It maintains a significant global footprint, supplying products to numerous international markets across Africa, Southeast Asia, and Latin America, supported by a robust distribution network for its extensive healthcare catalog.

Recent filings

Filing Released Lang Actions
Disclosure under SEBI Takeover Regulations
Major Shareholding Notification Classification · 95% confidence The document contains detailed information about share transactions, including dates, number of shares acquired or disposed, percentage of total equity share capital, names of promoters or persons in the promoter group, and references to SEBI regulations related to substantial acquisition of shares and takeovers. This matches the description of a Major Shareholding Notification, which reports changes in significant share ownership levels crossing thresholds. The document is not an announcement of a report, nor does it contain financial statements or management commentary. Therefore, the appropriate classification is Major Shareholding Notification (MRQ). The document length is short but contains substantive data about shareholding changes, confirming the classification with high confidence.
2022-06-18 English
Related Party Transaction
Regulatory Filings
2022-06-02 English
Newspaper Advertisements
Regulatory Filings
2022-05-27 English
Newspaper Advertisements
Regulatory Filings
2022-05-20 English
General updates
Regulatory Filings Classification · 95% confidence The document is very short (587 characters) and appears to be a formal communication addressed to stock exchanges (NSE and BSE) regarding a company named ICL Pharmaceuticals Limited. There is no substantive financial data, detailed report content, or analysis present. The text resembles a regulatory announcement or filing rather than a full report or detailed disclosure. Given the brevity and the nature of the addressees (listing departments), this is likely a Regulatory Filing (RNS) rather than a full Annual Report, Interim Report, or other detailed filings. There is no indication of voting results, management changes, or financial results. Therefore, the best classification is Regulatory Filings (RNS).
2022-05-19 English
Financial Result Updates
Regulatory Filings
2022-05-19 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.